76 Results
Sort By:
Published on October 12, 2023
China-headquartered MediLink Therapeutics has entered into a deal with BioNTech for development of a next-generation antibody-drug conjugate candidate (ADC) against Human Epidermal Growth Factor Receptor 3 (HER3). With an upfront payment of $70M and plenty of additional development, regulatory, and commercial milestone payments, the deal could be worth over $1 billion.…
Published on April 4, 2023
The field of ADCs is heating up, as the FDA just granted PADCEV (Seagen’s enfortumab vedotin-ejfv) and KEYTRUDA (Merck’s pembrolizumab) accelerated approval as a combination therapy for the treatment of certain adult patients with advanced urothelial cancer. Final approval is contingent upon results from a follow up trial (EV-302). Antibody drug conjugates (ADCs) are…
Published on November 6, 2024
Men with treatment-emergent neuroendocrine prostate cancer (t-NEPC) could benefit from human epidermal growth factor receptor (HER)2 testing and treatment with trastuzumab deruxtecan (T-DXd), suggest researchers from the Washington DC Veterans Affairs Medical Center and The George Washington University School of Medicine. They report in the Annals of Internal Medicine, the…
Published on August 5, 2024
Ideaya Biosciences is paying $400M+ for an option on Biocytogen Pharmaceuticals’ potential first-in-class B7H3/PTK7 BsADC program. Antibody drug conjugates (ADCs) combine the specificity of monoclonal antibodies with cytotoxic drugs aimed at delivering highly targeted treatment. Biocytogen says B7H3/PTK7 is co-expressed in multiple solid tumor types, including having double-digit percent prevalence…
Published on July 3, 2024
Eisai and Bristol Myers Squibb are ending their $650M collaboration for the co-development and co-commercialization of antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC), due to “ongoing portfolio prioritization efforts within Bristol Myers Squibb (BMS).” Formerly known as MORAb-202, FZEC is a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC). Eisai and…
Published on June 4, 2024
Breakthrough cancer drug Enhertu (trastuzumab deruxtecan) appears to have scored another first, this time in a trial of metastatic breast cancer patients with HER2-low and HER2-ultralow tumors. Researchers also presented the first data supporting Enhertu as a first-line treatment in HER2-positive metastatic breast cancer. Further, interim results from the DESTINY-Breast07…
Published on May 16, 2024
VIEW NOW Broadcast Date: June 11, 2024Time: 9:00 am PT, 12:00 PM, 18:00 CET This groundbreaking IPM Live webinar featured a conversation with renowned NCI/NIH researchers and co-authors Wendy Rubinstein and Christos Patriotis as they delve into their new research paper, “Cancer screening with multicancer detection tests: A translational science review.” This…
Published on January 30, 2024
One of the most competitive fields in pharma today involves antibody drug conjugates (ADCs), a market estimated to be worth almost $20B already. This week the FDA accepted the supplemental Biologics License Application (sBLA) for ADC Enhertu (fam-trastuzumab deruxtecan-nxki) and granted it Priority Review. Enhertu is a HER2-directed ADC being…
Published on January 5, 2024
Roche has inked a collaboration potentially worth more than $2B with precision oncology company MOMA Therapeutics. The deal provides the big pharma with access to MOMA’s proprietary KnowledgeBase platform, which was built to identify novel drug targets involved in promoting cancer cell growth and survival. This follows a $50 million…
Published on December 19, 2023
Two new deals around antibody drug conjugates (ADCs) were just struck. Pfizer will develop and commercialize Nona Biosciences’ MSLN-targeted ADC HBM9033 in a deal worth potentially $1B+. Meanwhile, Biocytogen Pharmaceuticals announced an antibody evaluation, option, and license agreement with Ona Therapeutics. The deal includes an option to exclusively license selected…
Published on December 12, 2023
Bristol Myers Squibb (BMS) will co-develop SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC) in the United States. The deal is worth potentially more than $8B. “Recent BL-B01D1 trials have shown broad potential across different solid tumors as well as a manageable safety profile,” said Yi Zhu, CEO…
Published on December 1, 2023
AbbVie continues the ADC party and beefs up its anti-solid tumor portfolio with the acquisition of ImmunoGen for $10.1B. ImmuoGen’s flagship cancer therapy is Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), according to an announcement yesterday. This has been the year of the…
Published on October 20, 2023
In a $4B upfront deal, Merck is acquiring three of Daiichi Sankyo’s antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). The two companies will jointly develop and commercialize these drugs worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Total potential consideration…
Published on September 7, 2023
Scientists at Montefiore Einstein Cancer Center (MECC) have developed a new test for detecting a type of cervical cancer that is often missed by traditional Pap tests. This breakthrough could have significant implications for cervical cancer screening. The findings of their research are published in the Journal of the National…
Published on May 18, 2023
Sony Corporation and Astellas Pharma have signed an agreement to discover a novel antibody-drug conjugate (ADC) platform in oncology based on Sony’s unique polymeric material—the KIRAVIA Backbone, which is made using the same organic polymer technology incorporated in the company’s proprietary KIRAVIA dyesTM. Terms of the deal were not released.…